标普和纳斯达克内在价值 联系我们

Invitae Corporation NVTA NYSE

NYSE • Healthcare • Medical - Diagnostics & Research • US • USD

SharesGrow Score
38/100
1/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$9.75
+51215.8%
SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Invitae Corporation (NVTA) .

本页证实的标准:

  • VALUE (100/100, 通过) — 分析师目标价暗示上行空间 (+51215.8%).
  • 分析师共识目标价 $9.75 (+51215.8% 上行空间) — 华尔街分析师认为存在显著上行潜力。

SharesGrow 综合评分: 38/100 其中 1/7 项标准通过。

SharesGrow 7-Criteria Score
38/100
SG Score
View full scorecard →
价值
100/100
Price-to-Earnings & upside
Proven by this page
~
未來
52/100
Analyst consensus
→ Forecast
过去
0/100
→ Income
健康
33/100
Debt-to-Equity & liquidity
→ Health
护城河
15/100
→ Income
~
成长
58/100
→ Income
收入
10/100
→ Income

估值概览 — NVTA

估值倍数
P/E (TTM)0.0
前瞻 P/EN/A
PEG 比率N/A
前瞻 PEGN/A
P/B 比率0.00
P/S 比率0.01
EV/EBITDA0.0
每股数据
EPS (TTM)$-13.18
每股账面价值$0.00
每股营收$2.19
每股自由现金流$0.00
收益率与内在价值
盈利收益率N/A
股息收益率0.00%
分析师目标价$9.75 (+51215.8%)

EPS:实际 vs 预期

P/E Ratio & Earnings Yield

每股收益 (EPS) 历史

Year EPS(稀释) 营收 净利润 净利润率
2013 $-1.67 $148K $-24.84M -16782.4%
2014 $-1.60 $1.6M $-47.67M -2971.8%
2015 $-3.18 $8.38M $-89.78M -1071.6%
2016 $-3.02 $25.05M $-100.26M -400.3%
2017 $-2.65 $68.22M $-123.38M -180.9%
2018 $-1.94 $147.7M $-129.36M -87.6%
2019 $-2.66 $216.82M $-241.97M -111.6%
2020 $-4.52 $279.6M $-608.87M -217.8%
2021 $-1.80 $460.45M $-379.01M -82.3%
2022 $-13.18 $516.3M $-3.11B -601.6%
联系我们
🎓
SharesGrow 学院
学习如何计算内在价值,发现被低估的股票。
每周在线课程
给我们留言